Oncolytics Biotech Inc. announced updates on the enrollment progress and expected data readouts from its ongoing GOBLET trial, which evaluates pelareorep in gastrointestinal cancers. For Cohort 4, studying pelareorep with atezolizumab in relapsed, unresectable squamous cell carcinoma of the anal canal (SCAC), enrollment is currently at 20 evaluable patients and is expected to be completed by the end of 2025. The company anticipates providing an efficacy update for this cohort in the fourth quarter of 2025.
In Cohort 5, which evaluates pelareorep in combination with modified FOLFIRINOX with or without atezolizumab for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), enrollment is approximately 40% complete. Full enrollment for this cohort is expected by the end of 2026, with an interim efficacy update, including overall survival, projected for the first quarter of 2026.
A significant development is the submission of a protocol amendment to allow the GOBLET study to open U.S. clinical sites within the next few months. Upon approval, institutions like Northwestern University are expected to serve as U.S. sites, broadening the scope and impact of the data and providing more patients with access to this important study.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.